Hoth Change To Liabilities vs Change In Cash Analysis

HOTH Stock

USD 0.85 0.01 1.16%

Hoth Therapeutics financial indicator trend analysis is much more than just examining Hoth Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hoth Therapeutics is a good investment. Please check the relationship between Hoth Therapeutics Change To Liabilities and its Change In Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

Change To Liabilities vs Change In Cash

Change To Liabilities vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hoth Therapeutics Change To Liabilities account and Change In Cash. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Hoth Therapeutics' Change To Liabilities and Change In Cash is 0.17. Overlapping area represents the amount of variation of Change To Liabilities that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Hoth Therapeutics, assuming nothing else is changed. The correlation between historical values of Hoth Therapeutics' Change To Liabilities and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Liabilities of Hoth Therapeutics are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Change To Liabilities i.e., Hoth Therapeutics' Change To Liabilities and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Change To Liabilities

Change In Cash

Most indicators from Hoth Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hoth Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.As of now, Hoth Therapeutics' Selling General Administrative is increasing as compared to previous years. The Hoth Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to 26.71, while Issuance Of Capital Stock is projected to decrease to under 9.4 M.

Hoth Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Retained Earnings Total Equity
Total Assets		0.88	0.8	1.0	0.92	0.45	-0.93	-0.88	0.44	0.97	0.64	0.0	1.0	0.92	-0.64	0.32	0.9	0.94	0.82	1.0	0.45	1.0	1.0	0.54	-0.81	-0.9
Other Current Liab	0.88		0.94	0.84	0.9	0.43	-0.87	-0.91	0.59	0.9	0.35	-0.08	0.88	0.84	-0.69	0.28	0.84	0.95	0.93	0.84	0.43	0.88	0.85	0.2	-0.79	-0.83
Total Current Liabilities	0.8	0.94		0.74	0.83	0.26	-0.78	-0.85	0.81	0.8	0.36	0.16	0.8	0.81	-0.76	0.49	0.81	0.87	0.99	0.74	0.26	0.8	0.75	0.21	-0.82	-0.84
Total Stockholder Equity	1.0	0.84	0.74		0.9	0.47	-0.92	-0.86	0.37	0.97	0.65	-0.02	1.0	0.9	-0.6	0.28	0.88	0.93	0.76	1.0	0.47	0.99	1.0	0.56	-0.78	-0.87
Net Tangible Assets	0.92	0.9	0.83	0.9		0.67	-0.99	-0.99	0.39	0.92	0.42	-0.06	0.92	0.83	-0.61	0.16	0.94	0.94	0.83	0.9	0.67	0.92	0.91	0.24	-0.75	-0.9
Property Plant And Equipment Net	0.45	0.43	0.26	0.47	0.67		-0.69	-0.69	-0.29	0.52	-0.05	-0.2	0.45	0.36	-0.22	-0.37	0.57	0.53	0.22	0.47	1.0	0.46	0.47	-0.22	-0.31	-0.41
Net Debt	-0.93	-0.87	-0.78	-0.92	-0.99	-0.69		0.96	-0.32	-0.95	-0.4	0.12	-0.94	-0.8	0.55	-0.09	-0.89	-0.92	-0.78	-0.92	-0.69	-0.94	-0.93	-0.29	0.7	0.84
Retained Earnings	-0.88	-0.91	-0.85	-0.86	-0.99	-0.69	0.96		-0.41	-0.9	-0.37	-0.01	-0.88	-0.85	0.66	-0.19	-0.94	-0.95	-0.84	-0.86	-0.69	-0.89	-0.87	-0.15	0.8	0.9
Accounts Payable	0.44	0.59	0.81	0.37	0.39	-0.29	-0.32	-0.41		0.41	0.31	0.48	0.44	0.56	-0.61	0.76	0.44	0.5	0.8	0.37	-0.29	0.44	0.38	0.24	-0.63	-0.55
Cash	0.97	0.9	0.8	0.97	0.92	0.52	-0.95	-0.9	0.41		0.45	-0.09	0.98	0.86	-0.53	0.18	0.84	0.96	0.79	0.97	0.52	0.98	0.97	0.37	-0.73	-0.82
Non Current Assets Total	0.64	0.35	0.36	0.65	0.42	-0.05	-0.4	-0.37	0.31	0.45		0.34	0.61	0.7	-0.65	0.67	0.64	0.46	0.47	0.65	-0.05	0.61	0.63	0.87	-0.7	-0.71
Non Currrent Assets Other	0.0	-0.08	0.16	-0.02	-0.06	-0.2	0.12	-0.01	0.48	-0.09	0.34		-0.02	0.27	-0.44	0.8	0.18	0.04	0.14	-0.02	-0.2	-0.01	-0.03	0.2	-0.45	-0.23
Cash And Short Term Investments	1.0	0.88	0.8	1.0	0.92	0.45	-0.94	-0.88	0.44	0.98	0.61	-0.02		0.91	-0.61	0.3	0.89	0.95	0.81	1.0	0.45	1.0	1.0	0.51	-0.8	-0.89
Common Stock Total Equity	0.92	0.84	0.81	0.9	0.83	0.36	-0.8	-0.85	0.56	0.86	0.7	0.27	0.91		-0.77	0.55	0.93	0.93	0.84	0.9	0.36	0.91	0.9	0.45	-0.94	-0.95
Common Stock Shares Outstanding	-0.64	-0.69	-0.76	-0.6	-0.61	-0.22	0.55	0.66	-0.61	-0.53	-0.65	-0.44	-0.61	-0.77		-0.73	-0.79	-0.66	-0.77	-0.6	-0.22	-0.63	-0.59	-0.44	0.93	0.8
Non Current Liabilities Total	0.32	0.28	0.49	0.28	0.16	-0.37	-0.09	-0.19	0.76	0.18	0.67	0.8	0.3	0.55	-0.73		0.41	0.3	0.53	0.28	-0.37	0.31	0.27	0.54	-0.71	-0.53
Capital Surpluse	0.9	0.84	0.81	0.88	0.94	0.57	-0.89	-0.94	0.44	0.84	0.64	0.18	0.89	0.93	-0.79	0.41		0.91	0.84	0.88	0.57	0.89	0.88	0.36	-0.9	-0.98
Other Stockholder Equity	0.94	0.95	0.87	0.93	0.94	0.53	-0.92	-0.95	0.5	0.96	0.46	0.04	0.95	0.93	-0.66	0.3	0.91		0.87	0.93	0.53	0.95	0.93	0.26	-0.84	-0.9
Total Liab	0.82	0.93	0.99	0.76	0.83	0.22	-0.78	-0.84	0.8	0.79	0.47	0.14	0.81	0.84	-0.77	0.53	0.84	0.87		0.76	0.22	0.82	0.77	0.29	-0.84	-0.88
Net Invested Capital	1.0	0.84	0.74	1.0	0.9	0.47	-0.92	-0.86	0.37	0.97	0.65	-0.02	1.0	0.9	-0.6	0.28	0.88	0.93	0.76		0.47	0.99	1.0	0.56	-0.78	-0.87
Property Plant And Equipment Gross	0.45	0.43	0.26	0.47	0.67	1.0	-0.69	-0.69	-0.29	0.52	-0.05	-0.2	0.45	0.36	-0.22	-0.37	0.57	0.53	0.22	0.47		0.46	0.47	-0.22	-0.31	-0.41
Total Current Assets	1.0	0.88	0.8	0.99	0.92	0.46	-0.94	-0.89	0.44	0.98	0.61	-0.01	1.0	0.91	-0.63	0.31	0.89	0.95	0.82	0.99	0.46		1.0	0.52	-0.81	-0.89
Net Working Capital	1.0	0.85	0.75	1.0	0.91	0.47	-0.93	-0.87	0.38	0.97	0.63	-0.03	1.0	0.9	-0.59	0.27	0.88	0.93	0.77	1.0	0.47	1.0		0.54	-0.78	-0.87
Common Stock	0.54	0.2	0.21	0.56	0.24	-0.22	-0.29	-0.15	0.24	0.37	0.87	0.2	0.51	0.45	-0.44	0.54	0.36	0.26	0.29	0.56	-0.22	0.52	0.54		-0.46	-0.45
Property Plant Equipment	-0.81	-0.79	-0.82	-0.78	-0.75	-0.31	0.7	0.8	-0.63	-0.73	-0.7	-0.45	-0.8	-0.94	0.93	-0.71	-0.9	-0.84	-0.84	-0.78	-0.31	-0.81	-0.78	-0.46		0.92
Retained Earnings Total Equity	-0.9	-0.83	-0.84	-0.87	-0.9	-0.41	0.84	0.9	-0.55	-0.82	-0.71	-0.23	-0.89	-0.95	0.8	-0.53	-0.98	-0.9	-0.88	-0.87	-0.41	-0.89	-0.87	-0.45	0.92

Click cells to compare fundamentals

Hoth Therapeutics Account Relationship Matchups

Hoth Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.8M	5.2M	11.0M	6.8M	9.5M	5.8M
Other Current Liab	36.2K	182.7K	506.8K	692.7K	585.4K	347.6K
Total Current Liabilities	440.1K	312.1K	867.8K	1.4M	678.7K	641.9K
Total Stockholder Equity	2.4M	4.6M	9.9M	5.1M	8.8M	5.1M
Net Tangible Assets	154.7K	2.4M	4.6M	9.9M	11.4M	11.9M
Net Debt	(1.7M)	(2.6M)	(8.5M)	(6.4M)	(9.2M)	(8.8M)
Retained Earnings	(12.2M)	(19.4M)	(33.7M)	(45.1M)	(52.9M)	(50.3M)
Accounts Payable	403.9K	129.5K	361.0K	695.0K	35.6K	33.8K
Cash	1.7M	2.6M	8.5M	6.4M	9.3M	4.7M
Non Current Assets Total	201.0K	460K	410K	33K	92.6K	87.9K
Non Currrent Assets Other	200K	50K	0.0	33K	(1.0)	(0.95)
Cash And Short Term Investments	2.5M	4.7M	10.4M	6.6M	9.3M	5.5M
Common Stock Shares Outstanding	366.6K	494.5K	893.2K	1.2M	3.4M	1.8M
Liabilities And Stockholders Equity	2.8M	5.2M	11.0M	6.8M	9.5M	5.8M
Non Current Liabilities Total	403.9K	285K	235K	250K	26.3K	25.0K
Other Stockholder Equity	14.6M	24.1M	43.6M	50.2M	61.7M	31.8M
Total Liab	440.1K	597.1K	1.1M	1.6M	705.0K	767.0K
Net Invested Capital	2.4M	4.6M	9.9M	5.1M	8.8M	5.1M
Total Current Assets	2.6M	4.8M	10.6M	6.7M	9.4M	5.6M
Accumulated Other Comprehensive Income	0.0	(15.4K)	17.6K	22.0K	27.3K	28.6K
Net Working Capital	2.2M	4.5M	9.7M	5.3M	8.7M	5.0M
Common Stock	1.0K	1.3K	2.4K	130.0	435.0	413.25
Other Current Assets	140.6K	89.8K	94.0K	88.5K	135.4K	102.3K
Capital Stock	1.0K	1.3K	2.4K	130.0	435.0	818.0

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:

How To Invest In Hoth

Details

Is Hoth Stock a good investment?

Details

What is Hoth Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.27)

Return On Assets

(0.46)

Return On Equity

(0.83)

The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hoth Change To Liabilities vs Change In Cash Analysis

Change To Liabilities vs Change In Cash

Change To Liabilities vs Change In Cash Correlation Analysis

Correlation Coefficient

Change To Liabilities

Change In Cash

Hoth Therapeutics fundamental ratios Correlations

Hoth Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hoth Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Retained Earnings	- 0.99	Net Tangible Assets
Net Debt	- 0.99	Net Tangible Assets
Retained Earnings Total Equity	- 0.98	Capital Surpluse
Retained Earnings Total Equity	- 0.95	Common Stock Total Equity
Other Stockholder Equity	- 0.95	Retained Earnings
Cash	- 0.95	Net Debt